Factors affecting the introduction of new vaccines to poor nations: A comparative study of the Haemophilus influenzae type B and hepatitis B vaccines

Aharona Glatman-Freedman, Mary Louise Cohen, Katherine A. Nichols, Robert F. Porges, Ivy Rayos Saludes, Kevin Steffens, Victor G. Rodwin, David W. Britt

Research output: Contribution to journalArticle

Abstract

Background: A major effort to introduce new vaccines into poor nations of the world was initiated in recent years with the help of the GAVI alliance. The first vaccines introduced have been the Haemophilus influenzae type B (Hib) and the hepatitis B (Hep B) vaccines. The introduction of these vaccines during the first phase of GAVI's operations demonstrated considerable variability. We set out to study the factors affecting the introduction of these vaccines. The African Region (AFRO), where new vaccines were introduced to a substantial number of countries during the first phase of GAVI's funding, was selected for this study. Methodology/Principal Findings: GAVI-eligible AFRO countries with a population of 0.5 million or more were included in the study. Countries were analyzed and compared for new vaccine introduction, healthcare indicators, financial indicators related to healthcare and country-level Governance Indicators, using One Way ANOVA, correlation analysis and Qualitative Comparative Analysis (QCA). Introduction of new vaccines into AFRO nations was associated primarily with high countrylevel Governance Indicator scores. The use of individual Governance Indicator scores, as well as a combined Governance Indicator score we developed, demonstrated similar results. Conclusions/Significance: Our study results indicate that good country-level governance is an imperative pre-requisite for the successful early introduction of new vaccines into poor African nations. Enhanced support measures may be required to effectively introduce new vaccines to countries with low governance scores. The combined governance score we developed may thus constitute a useful tool for helping philanthropic organizations make decisions regarding the type of support needed by different countries to achieve success.

Original languageEnglish (US)
Article numbere13802
JournalPLoS One
Volume5
Issue number11
DOIs
StatePublished - 2010

Fingerprint

Haemophilus influenzae
Hepatitis B Vaccines
hepatitis B
Vaccines
governance
vaccines
funding
health services
Delivery of Health Care
Analysis of variance (ANOVA)
Analysis of Variance
analysis of variance

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Glatman-Freedman, A., Cohen, M. L., Nichols, K. A., Porges, R. F., Saludes, I. R., Steffens, K., ... Britt, D. W. (2010). Factors affecting the introduction of new vaccines to poor nations: A comparative study of the Haemophilus influenzae type B and hepatitis B vaccines. PLoS One, 5(11), [e13802]. https://doi.org/10.1371/journal.pone.0013802

Factors affecting the introduction of new vaccines to poor nations : A comparative study of the Haemophilus influenzae type B and hepatitis B vaccines. / Glatman-Freedman, Aharona; Cohen, Mary Louise; Nichols, Katherine A.; Porges, Robert F.; Saludes, Ivy Rayos; Steffens, Kevin; Rodwin, Victor G.; Britt, David W.

In: PLoS One, Vol. 5, No. 11, e13802, 2010.

Research output: Contribution to journalArticle

Glatman-Freedman, Aharona ; Cohen, Mary Louise ; Nichols, Katherine A. ; Porges, Robert F. ; Saludes, Ivy Rayos ; Steffens, Kevin ; Rodwin, Victor G. ; Britt, David W. / Factors affecting the introduction of new vaccines to poor nations : A comparative study of the Haemophilus influenzae type B and hepatitis B vaccines. In: PLoS One. 2010 ; Vol. 5, No. 11.
@article{7c8b51e0f0e241ce85ce192559b3b8f2,
title = "Factors affecting the introduction of new vaccines to poor nations: A comparative study of the Haemophilus influenzae type B and hepatitis B vaccines",
abstract = "Background: A major effort to introduce new vaccines into poor nations of the world was initiated in recent years with the help of the GAVI alliance. The first vaccines introduced have been the Haemophilus influenzae type B (Hib) and the hepatitis B (Hep B) vaccines. The introduction of these vaccines during the first phase of GAVI's operations demonstrated considerable variability. We set out to study the factors affecting the introduction of these vaccines. The African Region (AFRO), where new vaccines were introduced to a substantial number of countries during the first phase of GAVI's funding, was selected for this study. Methodology/Principal Findings: GAVI-eligible AFRO countries with a population of 0.5 million or more were included in the study. Countries were analyzed and compared for new vaccine introduction, healthcare indicators, financial indicators related to healthcare and country-level Governance Indicators, using One Way ANOVA, correlation analysis and Qualitative Comparative Analysis (QCA). Introduction of new vaccines into AFRO nations was associated primarily with high countrylevel Governance Indicator scores. The use of individual Governance Indicator scores, as well as a combined Governance Indicator score we developed, demonstrated similar results. Conclusions/Significance: Our study results indicate that good country-level governance is an imperative pre-requisite for the successful early introduction of new vaccines into poor African nations. Enhanced support measures may be required to effectively introduce new vaccines to countries with low governance scores. The combined governance score we developed may thus constitute a useful tool for helping philanthropic organizations make decisions regarding the type of support needed by different countries to achieve success.",
author = "Aharona Glatman-Freedman and Cohen, {Mary Louise} and Nichols, {Katherine A.} and Porges, {Robert F.} and Saludes, {Ivy Rayos} and Kevin Steffens and Rodwin, {Victor G.} and Britt, {David W.}",
year = "2010",
doi = "10.1371/journal.pone.0013802",
language = "English (US)",
volume = "5",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "11",

}

TY - JOUR

T1 - Factors affecting the introduction of new vaccines to poor nations

T2 - A comparative study of the Haemophilus influenzae type B and hepatitis B vaccines

AU - Glatman-Freedman, Aharona

AU - Cohen, Mary Louise

AU - Nichols, Katherine A.

AU - Porges, Robert F.

AU - Saludes, Ivy Rayos

AU - Steffens, Kevin

AU - Rodwin, Victor G.

AU - Britt, David W.

PY - 2010

Y1 - 2010

N2 - Background: A major effort to introduce new vaccines into poor nations of the world was initiated in recent years with the help of the GAVI alliance. The first vaccines introduced have been the Haemophilus influenzae type B (Hib) and the hepatitis B (Hep B) vaccines. The introduction of these vaccines during the first phase of GAVI's operations demonstrated considerable variability. We set out to study the factors affecting the introduction of these vaccines. The African Region (AFRO), where new vaccines were introduced to a substantial number of countries during the first phase of GAVI's funding, was selected for this study. Methodology/Principal Findings: GAVI-eligible AFRO countries with a population of 0.5 million or more were included in the study. Countries were analyzed and compared for new vaccine introduction, healthcare indicators, financial indicators related to healthcare and country-level Governance Indicators, using One Way ANOVA, correlation analysis and Qualitative Comparative Analysis (QCA). Introduction of new vaccines into AFRO nations was associated primarily with high countrylevel Governance Indicator scores. The use of individual Governance Indicator scores, as well as a combined Governance Indicator score we developed, demonstrated similar results. Conclusions/Significance: Our study results indicate that good country-level governance is an imperative pre-requisite for the successful early introduction of new vaccines into poor African nations. Enhanced support measures may be required to effectively introduce new vaccines to countries with low governance scores. The combined governance score we developed may thus constitute a useful tool for helping philanthropic organizations make decisions regarding the type of support needed by different countries to achieve success.

AB - Background: A major effort to introduce new vaccines into poor nations of the world was initiated in recent years with the help of the GAVI alliance. The first vaccines introduced have been the Haemophilus influenzae type B (Hib) and the hepatitis B (Hep B) vaccines. The introduction of these vaccines during the first phase of GAVI's operations demonstrated considerable variability. We set out to study the factors affecting the introduction of these vaccines. The African Region (AFRO), where new vaccines were introduced to a substantial number of countries during the first phase of GAVI's funding, was selected for this study. Methodology/Principal Findings: GAVI-eligible AFRO countries with a population of 0.5 million or more were included in the study. Countries were analyzed and compared for new vaccine introduction, healthcare indicators, financial indicators related to healthcare and country-level Governance Indicators, using One Way ANOVA, correlation analysis and Qualitative Comparative Analysis (QCA). Introduction of new vaccines into AFRO nations was associated primarily with high countrylevel Governance Indicator scores. The use of individual Governance Indicator scores, as well as a combined Governance Indicator score we developed, demonstrated similar results. Conclusions/Significance: Our study results indicate that good country-level governance is an imperative pre-requisite for the successful early introduction of new vaccines into poor African nations. Enhanced support measures may be required to effectively introduce new vaccines to countries with low governance scores. The combined governance score we developed may thus constitute a useful tool for helping philanthropic organizations make decisions regarding the type of support needed by different countries to achieve success.

UR - http://www.scopus.com/inward/record.url?scp=78149485218&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78149485218&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0013802

DO - 10.1371/journal.pone.0013802

M3 - Article

C2 - 21072192

AN - SCOPUS:78149485218

VL - 5

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 11

M1 - e13802

ER -